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Welcome to the inaugural issue
of Advance, a biannual research
digest for alumni, friends and
colleagues.
Advance is produced by the
University of Tennessee Graduate
School of Medicine to highlight
the wide-ranging research and
people who are part of the
research enterprise of the region’s
only academic medical center: the
University of Tennessee Medical
Center and UT Graduate School
of Medicine.
We are grateful to the leaders of
University of Tennessee Medical Center for their support of this
communication and for their unflagging support of the spirit of
inquiry that pervades our institutions. In addition to excellence in
patient care and education, our academic medical center sponsors
extensive research in both the clinical and laboratory settings. In
that endeavor, we collaborate with the University of Tennessee,
Knoxville (UTK), UT College of Veterinary Medicine, Oak Ridge
National Laboratory (ORNL) and other research institutions to
seek answers to complex medical problems. We train students,
physicians and scientists to become the researchers of the future
and approach health care with the curiosity that will lead to
improvement in the lives of our patients.
Research and researchers, alike, take many forms. Some of
our researchers have taken clinical problems to the laboratory and
are delving into very fundamental questions on the molecular
level. Some are clinicians performing prospective trials of new
techniques or treatments. Others are trying to find ways to
improve the delivery of healthcare by looking retrospectively in
order to parse out clues to enhance future outcomes.
In partnership with our colleagues at UTK, we are looking
at medical care delivery and how decisions are made, hoping
to enhance patient safety and access as well as reduce the cost
of medical care. With ORNL, we are looking at how images
are interpreted with an eye to eventual computerization. The
UTK College of Engineering is helping develop new devices and
educational simulators for our physicians and scientists, so they
may effectively practice in our new Medical Simulation Center,
improving their skills in a virtual setting.
Our researchers are scientists dedicated to pure science, and
they are physicians who in addition to providing clinical care seek
answers through research that will also help their patients. It is
the nature of an academic medical center like ours to pursue new
solutions and solve diverse questions in the quest for excellence.
All of this intellectual vigor requires hefty funding and support
from the institutions. The immediate return is not always visible.
The UT Graduate School of Medicine supports the ongoing
research efforts because we understand that the atmosphere of
inquiry is vital to our mission of superior patient care
and education.
Our academic medical center sustains this effort through
its budget, grants from funding agencies and foundations and
through generous gifts from benefactors who understand the
crucial role medical research plays for our community and for
mankind. In addition, some departments and physicians allocate
portions of their practice income to research in areas of their
expertise.
The results, as you will see in this publication, create a robust
catalogue of outstanding work portending an exciting future for
the University of Tennessee Medical Center and the patients
we serve.
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featured researcher
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Alan Solomon, M.D.

Stone by stone, this laborer crafts walls and
pathways across his tranquil property. The
stonework, an avocation, is precise and lovely
and reflects the man’s drive and vision, traits that
define Alan Solomon, M.D., and his work at
the UT Graduate School of Medicine, where he
serves as professor of Medicine and directs the
Human Immunology and Cancer Program. He
has given most of his adult years as a physician
and medical researcher to improve the quality of
life of his patients.

at the National Institutes of Health’s National
Cancer Institute and The Rockefeller Institute for
Medical Research.
Finally, he finished his self-imposed rigors of
training and began working. Then the phone rang.

Tennessee Calling
“I got a call from Dr. Amoz Chernoff, who
was director of the UT Memorial Research
Center,” Solomon says. “He asked if I would be
interested in coming to Tennessee.”
The year was 1966. Medical research had few
regulations, and without the internet, researchers
waited months for new information to reach
library shelves. MRI, CT and PET scans did not
exist, and anti-cancer drugs were only a dream.
In this setting, Solomon came to UT where
his research and clinic duties were devoted
to cancer. In 1992, he was one of eight
medical scientists in the U.S. to be named an
American Cancer Society Clinical Research

North and South
A native New Yorker, Solomon graduated
from Duke University School of Medicine in
1957 and then completed an internship at
Mount Sinai Hospital in New York. He then did
something most medical school graduates did not
do: He chose to undergo another three years of
clinical training at Montefiore and Mount Sinai
hospitals, plus four years of research training
2

Professor. Subsequently, his efforts have focused
on a disease known as amyloidosis.
Amyloid is the term for a misfolded, “gum-upthe-works” form of a variety of proteins that can
form hair-like fibers, or fibrils, that are deposited
into vital organs, like the heart, kidneys, pancreas
or brain. This process leads to organ failure and
eventually, death. Amyloid-associated illnesses
include Alzheimer’s disease, adult (Type-2)
diabetes, rheumatoid arthritis and a condition
related to multiple myeloma called primary or
AL amyloidosis.
“The goal of our amyloid research is to
develop new means of diagnosis and more
effective treatment,” Solomon says. “We are
convinced that we can make a significant impact
on these diseases by improving the prognoses and
reducing the suffering of our patients.”
Today, the fruits of this research are being
applied directly to the patient.
“To see the discoveries in the laboratory
being translated to the clinic indeed is a major
achievement, but even though
these illnesses cannot be cured
at present, we will at least make
them more chronic and improve
the quality of life.”

in New York. He was the recipient of several
honorary doctoral degrees and four endowed
professorships in law and medicine.
Today, rooted in faith and family, backed by a
lifetime of wisdom and spurred by a passionate
quest, Solomon made a promise almost
15 years ago.
“A patient of mine had amyloid disease
and later died. At her funeral, I promised her
husband that we’d do something to affect this
disease that took his wife, and when I make a
promise, I try to keep it,” he says.
“I owe a debt of gratitude to my patients and
my talented colleagues who truly have been
partners in this work. I’m also thankful to the
private and public agencies that have provided
the financial support to fund our research.”
Just as one stone leads to the next, Solomon
remains optimistic that through his and his
colleagues’ research, advances in medicine will
lead to others to benefit all humanity.

Promise, Faith, Family
“Everyone, regardless of who
they are, can do something to
contribute to the healing of the
world,” Solomon says, reflecting
belief in a central Jewish tenant
and a strong paternal influence.
Solomon’s father came from a
very poor immigrant family and
dropped out of school at age
12 to support his family. He
found a way to go to school at
night and eventually completed
law school to become a senior
partner in a large law firm
3

SunScreeners
Taking It to the Streets: Research That’s More than Skin Deep

You might have seen him in his “sun
suit.” Sans jacket and tie, it’s a giant, friendly
sunshine. But the sun suit doesn’t just attract
attention. For Jim Lewis, M.D., assistant
professor of Surgery and surgical oncologist,
it’s a silly way to reach people about a
serious subject.
Skin cancers are,
indeed, serious, even
deadly, but they are
often preventable. More
than 120,000 people are
diagnosed each year with
melanoma, which is cancer
of the pigment cells and the
deadliest form of skin cancer.
Of those, about 45% are invasive,
resulting in someone dying from
melanoma every hour in the
U.S. Melanoma, if caught
early, can be cured
through surgery.
Other skin cancers also should not be
ignored: squamous cell carcinoma, cancer
of the outer layer of skin cells; and basal cell
carcinoma, cancer of the deepest layer of skin
cells and the most common skin cancer.
To help people understand the importance
of caring for their skin and identifying
abnormal skin lesions, Lewis, along with
Valerie Sams, M.D., third-year resident in
Surgery, and Georgette Samaras, UT Cancer
Institute’s outreach coordinator, have embarked
on a community outreach program,

Jim Lewis, M.D., in his “sun suit.”

Why this matters:

Early detection of melanoma and other skin cancers
can save a life.
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Advice from the
SunScreeners
Prevent Sunburn
Limit or avoid sun exposure between
10 a.m. and 4 p.m.

called SunScreeners. The program provides onsite skin screenings and allows community
members to enroll in a research program that
provides evaluation and diagnosis of skin lesions
and support for further examination by
a specialist.
“We believe we must educate people about
skin cancers,” Lewis said. “Early detection
leads to cures, so we take the opportunity for
screenings to the communities.”
Donning his sun suit, Lewis and his team set
up SunScreeners at outdoor sports events and
community festivals and visit senior centers and
wellness programs at area businesses.
Some community members just want to have
a skin blemish examined on the spot, but others
sign up for the research program, which includes
on-site dermal photography of the skin lesion.
“Using the dermal photography, we classify
lesions from benign [not harmful] to very
problematic,” Lewis said. “We will then contact
participants with results of their screenings and
for some, help them find a dermatologist or other
specialist. Six months later, we will follow up
with the participants to evaluate the effectiveness
of the program.
“We’ve screened more than one thousand
people, and the majority had only benign lesions.
For the small percent of people who were referred
to a specialist, we believe we potentially saved
their lives,” he concluded.
For more information about SunScreeners or
how you can participate in the research program,
contact Georgette Samaras at 865-305-8577.

Avoid Tanning Beds
Tanning bed users have 2.5 times the
risk of squamous cell carcinoma and 1.5
times the risk for basal cell carcinoma.
Exposure to tanning beds before age 35
increases melanoma risk by 75%.
Use Sunscreen
“SPF” refers to “sun protection
factor,” the amount of time you will
be protected from a burn. Use a
sunscreen with an SPF of 15 or higher.
Sunscreens should be liberally applied
about 20 minutes before sun exposure.

Melanoma:
What To Look For
Melanoma, the deadliest form of
skin cancer, can be identified in
several ways:
• A spot that is new, irregularly shaped
and dark brownish with darker or
black areas
• A mole that grows darker, bigger or
firmer, itches or tingles and/or flakes
and bleeds
• A lesion with an irregular border
• A bump that is shiny, firm and
dome shaped
• A dark lesion under a fingernail or
toenail or on the palm or sole.
If you are concerned about your skin,
call your doctor today.
5

Genetics and Concussion

Tom Terrell, M.D., and colleagues are investigating
a connection between genetics and concussion.

Concussion is an injury to the brain due to
rapid rotation of the head caused by trauma to the
head or other part of the body. It causes transient
alteration in the brain’s neurological status and can
have long-term effects. Loss of consciousness does
not necessarily accompany concussion.
In the study, athletes who sustain a concussion
voluntarily submit DNA samples, which are
analyzed at Duke University. The team is
investigating whether genetic polymorphisms
(variations in individual DNA sequence between
individuals) increase the risk of sustaining
concussion; influence the severity of acute sports
concussions; and impact the duration
of symptoms.
So far, 120 concussions have been collected,
and results of the genetic analysis are forthcoming.

Could your child be genetically predisposed
to a more severe concussion? Could his genetics
indicate a slower recovery from a concussion?
Tom Terrell, M.D, associate professor in
Family Medicine and associate director of the
Sports Medicine Fellowship, and Ken Bielak,
M.D., associate professor and Sports Medicine
Fellowship director, are leading a study to answer
those questions.
Terrell and Bielak are attempting to find a
biological link to the association between genetic
makeup and concussion risk in athletes. The
study is funded by the National Operating
Committee on Standards for Athletic Equipment
and is the largest prospective cohort study of its
kind in the U.S. It has the participation of 15
colleges and universities in the Southeast and
about 2,500 athletes in collision sports.

Why this matters:

Athletes suffer more than one million concussions
each year. As more light is shed on the serious
nature of brain injury, including concussion, we
learn more about how to care for our athletes
and accident victims.
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Concussion Center
The Department of Family Medicine
is establishing a Concussion
Center in its new Sports Medicine
Clinic to serve concussed athletes
in the community. The Sports
Medicine Clinic offers services from
sports medicine physicians for a
variety of sports- and non-sportsrelated accidents and injuries. For
information call 865-305-9352.

“We believe the study will reveal if there is genetic
predisposition to more severe concussions,” Terrell
said. “These findings may potentially determine
how quickly athletes should return to play or
whether they should play collision sports at all.
For those who have suffered concussions, our
findings might provide promising information
about the risk for additional concussions and the
duration of recovery time. With larger longterm studies, we may be able to predict who is
vulnerable to more severe concussions.”
This milestone in the research marks not an
ending but a springboard for further study. Terrell
and Bielak now are working with researchers in
the Molecular Imaging and Translational Research
Program as well as physicians in the Emergency
Department. The goal of this collaboration is
to ultimately help accident victims who suffer
brain injury and investigate new ways to image
concussion using positron emission tomography/
computed tomography (PET/CT).
For more information about the concussion
study or to register to participate in the study, visit
www.concussionresearch.com or contact Terrell at
865-305-9352.
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The ABCs of Clinical
Trials and How You
Can Benefit
William B. Smith, M.D., President, Volunteer Research Group

			

Individuals who participate in clinical trials
may benefit in a variety of ways:
• Playing a more active role in their own
health care
• Being involved in the discovery of new
treatments for those suffering from
various illnesses
• Gaining access to new research treatments
before they are widely available
• Undergoing medical examinations and lab
work at no cost and
• Possibly being compensated for their travel,
time and inconvenience.

Deborah Tuggle is participating in a clinical trial under the
direction of William Smith, M.D., and believes it’s her way to
help future generations.

Clinical trials are a type of medical research
conducted to collect data on the safety and
effectiveness of new treatments, most commonly
devices, vaccines or drugs.
Product development exists in four phases:
Phase I - Short trials evaluating basic safety
and metabolism
Phase II - Early evaluation of effectiveness,
safety and appropriate dose
Phase III - Large trials to determine efficacy
and side effects for submission to the FDA
for approval
Phase IV - Post-marketing studies to answer
additional questions about marketed drugs or
determine new indications.

“Clinical trials research offers an opportunity
for patients to be a part of the future of
medicine,” says Timothy Panella, M.D., chair
of Department of Medicine. “If people do not
participate in these studies, the advancement of
medical care comes to a standstill. We stand on
the shoulders of others, and the patients at the
top edge are those participating in clinical trials;
it’s altruism at its finest.”
Volunteer Research Group (VRG) is an entity
for pharmaceutical-sponsored clinical trials
located at the University of Tennessee Medical
Center. VRG currently is seeking volunteers
with high cholesterol, low kidney function,
liver disease, congestive heart failure or prior
myocardial infarction and for adults who are
generally healthy. For a complete list of enrolling
studies and to find out how you can become a
participant, visit www.VRGUT.com or
call 865-305-DRUG (3784).

“This is my way of contributing to future
generations,” says Deborah Tuggle, a clinical
trials participant. “Medicines that have helped
me in the past were developed through studies
just like these, and eventually these will help
someone. I like being a part of that process.”

Why this matters:

Clinical trials advance healthcare and bring
treatments more quickly to patients.
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In Brief
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Recipe for Success:
Surgery Residents

UT Graduate School of Medicine
surgical residents and faculty
physicians operate.

Why do some residents in the rigorous surgical
residency program succeed…and some do not?
Daniel Alterman, M.D., sixth-year resident in
General Surgery led a study to find out.
“Other studies have shown that gender,
marital status and ethnicity make a difference in
the success rate of surgical residents,” Alterman
said. “Our study found these factors make little
difference.”
Alterman says the study showed predictors of
good clinical and academic performance during
surgical residency are top scores on Step 1 of the

U.S. Medical Licensing Exam (USMLE), a good
interview impression and accomplishments in high
performance areas outside of medicine, such as
Division I college athletics and the performing arts.
These results add to the growing body of
literature that highlights the importance of the
USMLE Step 1 score as a key component in
resident screening and selection.

Next issue: Watch for resident research in
other departments.

Why this matters:

Now, the UT Graduate School of Medicine has
objective markers to help focus the screening
process for surgical residents, which will result
in more successful surgeons for the community.
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In Brief
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A New Disease on the Rise:
HPV-Related Oral Cancer
It’s a subject many people are too embarrassed
to discuss. Not so with Eric R. Carlson, D.M.D.,
M.D., chair of Oral and Maxillofacial Surgery.
His research is showing findings so startling that
he believes he must talk about it: The possible
association between oral cancer and intimate oral
contact.
For the first decade of Carlson’s practice
beginning in 1990, oral cancer in the patients
he treated was primarily caused by well accepted
carcinogens, namely tobacco and alcohol. The
patients were typically older men.
 	 Starting in 2000, Carlson began seeing young,
non-tobacco-using, otherwise healthy men
presenting with oral cancer, most commonly
tongue cancer. He believed the cancer might be
caused by human papillomavirus (HPV), a DNA
virus known to cause cervical cancer in women.
Carlson was right.
 	 After studying the patients’ tumors, he found
HPV in more than half of the specimens, and
more research has led to the belief that HPV is
likely transmitted through intimate oral contact.
 	 In cervical cancer, the incorporation of HPV in
a woman’s DNA can, under certain circumstances,
produce cancer proteins (oncoproteins) that
inhibit two important tumor suppressor genes.
Carlson believes this is the same process that can
cause cancer in the mouths and throats of people,
particularly those with more frequent exposure.

It is becoming well
accepted that more
frequent exposure to
the virus increases the
risk of developing an
HPV-related
oral cancer.
Even more shocking,
Eric R. Carlson,
		 D.M.D,
		
the American Medical
M.D.
				
Association recently
stated that 50% of men are HPV positive and
80% of women are HPV positive by the age of 50.
 	 “Over the past decade, societal practices have
changed,” Carlson said. “HPV-related oral cancer
is becoming more commonly observed, but we
are narrowing the gap in our knowledge of these
cancers. Next, we want to determine why some
men have HPV but do not develop oral cancer
and study the cancer of monogamous partners to
see if the HPV viruses match in men with HPVrelated oral cancers and their female partners with
HPV-related disease in the cervix. This scientific
observation will get us closer to concluding a
cause-and-effect relationship associated with this
social disease.”
 	 In the meantime, counseling young people
about the risks of exposure to HPV is imperative.
Also, HPV vaccines for both young women
and men between the ages of nine and 26
are available.

Why this matters:

We now know there are different types of oral
cancer: Those associated with HPV and oral
cancers not associated with HPV. An important
part of our observation is that patients with HPVrelated oral cancers have a better prognosis than
those patients with oral cancers associated with
the excessive use of tobacco and alcohol. Also,
revealing this social disease keeps our younger
population healthier.
10

In Brief
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Identifying How HRT and
Gene Therapy Affect Vascular Disease

Deidra Mountain, Ph.D., and
her team are researching causes
of vascular disease.

Estrogen and progesterone could be
contributing to vascular disease, and the
researchers in the Vascular Research Laboratory are
asking, “Why?” The team is using information
discovered years ago by physicians in the Division
of Vascular/Transplant Surgery that showed
women receiving hormone replacement therapy
(HRT) who also had vascular disease requiring
interventions often had more adverse outcomes
after their procedures than women who were
not undergoing HRT. The team is identifying
the vascular cell mechanisms that seem to be
influenced by the estrogen and progesterone in
HRT with the goal of developing ways to
help women.
Now, the team, led by Deidra Mountain,
Ph.D., assistant professor of Vascular/Transplant

Surgery, are continuing their fight against vascular
disease by examining gene therapy. Gene therapy
is the delivery of genetic material into a living cell
that incorporates the new genetic instructions
to alter a disease process. This type of therapy
shows promise in the treatment of many diseases,
including vascular, but delivering the genes in
a safe and non-toxic way has been a formidable
problem.
Mountain’s team is testing a delivery agent
made from biodegradable polymer that does
not have the harmful side effects of traditional
agents. They have successfully silenced (altered)
dysfunctional genes in laboratory tests and will
proceed with testing in biological samples. Success
here could lead to gene therapy for vascular disease
and research into many other diseases.

Why this matters:

Instead of treating symptoms of vascular disease,
gene therapy alters the function of genes that are
contributing to the disease, therefore, helping the
body heal itself or prevent the development of
the disease. Gene therapy could be an innovative
treatment for many diseases.
11

In Brief
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Dental Protein Could Improve
Breast Cancer Diagnosis
Daniel Kestler, Ph.D., Charles Bruker, M.D.,
and their colleagues in the Human Immunology
and Cancer Program have investigated a
protein, called ODAM (odontogenic ameloblast
associated), in certain odontogenic (dental) tumors.
Interestingly, it has been detected in breast, lung
and gastrointestinal cancers, melanoma and other
malignancies. The findings and discoveries on
this molecule could improve the diagnosis and
treatment of some cancers, of particular interest to
the team’s clinical members, surgical oncologists
John Bell, M.D., and James Lewis, M.D.
Proteins are the primary components of cells,
affecting their growth, function and regulation.
The researchers found that localization of the
ODAM protein in cells correlated with the stage
of breast cancer and melanoma, a cancer of skin’s
pigment cells. Further, the expression of the
ODAM protein was introduced into cultures of
highly invasive human breast tumor cells in the
laboratory, and the researchers saw significant
increase of tumor growth and invasiveness.
A number of patients who have participated
in the study also were found to have measurable
levels of antibodies to the protein in their blood.
“This suggests an immune recognition of this
protein as a possible tumor expressed antigen and
that the molecule or its interactions may prove

ODAM protein (fluorescent green) is photographed among
breast cancer cells (blue). The ODAM protein could help in
the diagnosis of breast and other cancers.

important for cancer evaluation and therapy,”
said Kestler.
If the protein can serve as a tumor biomarker (a
substance that can be traced in the body), cancers
can be diagnosed earlier or perhaps linked to
specific treatment, which might improve chances
for survival.
The protein, created by a natural gene
previously not known to produce a protein,
was first discovered in the Molecular Biology
Laboratory by Alan Solomon, M.D., director,
Human Immunology and Cancer Program.

Why this matters:

While a relatively low number of people who suffer
from certain dental tumors could benefit from
the identification of this novel protein, thousands
who suffer from breast, lung and other cancers
will benefit from the new research and possible
diagnostic treatment potentials that the studies
on ODAM will have opened.
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News»
Residents, Fellows
Present Research

Residents and fellows at the UT Graduate School of Medicine
review research presentations.

More than 40 residents and fellows presented
abstracts during Research Days that summarized
research in both case studies and original
projects. Topics included blood transfusion
in trauma; dental infection and correlation to
systemic illness; improving resident-patient
communication; MRSA infections in the head
and neck; gene therapy and others.
“Research Days are a direct extension of
the Graduate School of Medicine’s mission
to improve patient care through research and
scholarly activity,” said William Metheny,
assistant dean, Graduate Medical and Dental
Education. “The events are celebrations of the
culmination of faculty mentoring that teaches
the next generation the discipline of scientific
inquiry and discovery.”

NIH Grant Awarded for
Wound Healing Research
A research study jointly led by the UT Graduate
School of Medicine Shock, Trauma and
Nutrition laboratory and Advanced Plasma
Products Inc. received funding from the National
Institutes of Health. The Small Business
Innovation Research grant, totaling $341,000,
will fund research in the development of an
atmospheric plasma application to improve
wound healing.

Researcher Recognized
at Conference
Christopher Stephens, Ph.D., assistant professor,
Regenerative Medicine laboratory, received
an Award of Excellence at the Comparative
and Experimental Medicine and Public
Health Symposium held at the University of
Tennessee College of Veterinary Medicine. The
award recognized his research described in a
presentation, “Generation of Three-Dimensional
Tissue Using Stem Cell Seeding of Polymeric
Scaffolds.”

Your Chance to Advance
The people at the UT Graduate School of Medicine would be happy
to discuss our research programs and how your support can help advance
healthcare. For information about philanthropic giving to the UT
Graduate School of Medicine Office of Research, please contact the
development office at 865-305-6611 or development@utmck.edu.
If you would like more information about any of the research
programs described in this issue of Advance, please contact the UT
Graduate School of Medicine at 865-305-9290 or visit us online:
http://gsm.utmck.edu/research/main.cfm.
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